Cabometyx-Nivolumab Combo Improves Survival in Advanced RCC, Study Results Show
In early stages, renal cell carcinoma (RCC) is treatable and has a high five-year survival rate. However, if the cancer progresses or metastasizes (spreads), the five-year survival rate falls…